Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07010250
Recruiting Observational

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

NCT07010250 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2025-11-03
Last updated
2026-06-30

Condition(s) studied

ANCA Associated VasculitisExtramembranous GlomerulopathyNephrotic Syndrome, Minimal ChangeInterstitial NephritisIgA NephropathySegmental HyalinosisDiabetic Nephropathies

Study summary

The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with an indication for initial diagnostic PBR on native kidney * 18 ans ≥ Age ≤ 90 ans * Affiliation to french health insurance * Patient having given consent For the ANCA vasculitis group: • Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO) For the control groups: • Diagnosis retained after the renal biopsy * Interstitial Nephritis * Or glomerular nephropathy such as minimal change nephropathy * Or Segmental hyalinosis in itscollapsing form * Or Extramembranous Glomerulopathy, * Or glomerulopathy with mesangial IgA deposits * Or diabetic nephropathy. Exclusion Criteria: * Kidney transplant patient * Patient on dialysis (hemodialysis or peritoneal dialysis) * Patient under legal protection, guardianship or curatorship * Pregnancy or breastfeeding * Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.

Primary outcome measure(s)

  • Spatial lipidomics for measuring tubular dysmetabolism — Through study completion up to end of study, when the last patients completed 1 year follow-up.
    Measured either through biospy at baseline or from blood and urine samples taken at baseline, after 15 days, 2 months, 6 months and then every 6 months until the last patients completed 1 year follow-up. Their contribution for classifying ANCA vasculitis and other nephropathies will be evaluated.
  • Co-staining for measuring tubular segments markers — Through study completion up to end of study, when the last patients completed 1 year follow-up
    Measured either through biospy at baseline or from blood and urine samples taken at baseline, after 15 days, 2 months, 6 months and then every 6 months until the last patients completed 1 year follow-up. Their contribution for classifying ANCA vasculitis and other nephropathies will be evaluated.
  • Immunofluorescence (at the protein level) for measuring peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma) — Through study completion up to end of study, when the last patients completed 1 year follow-up
    Measured either through biospy at baseline or from blood and urine samples taken at baseline, after 15 days, 2 months, 6 months and then every 6 months until the last patients completed 1 year follow-up. Its contribution for classifying ANCA vasculitis and other nephropathies will be evaluated.
  • Spatial transcriptomics (at the mRNA level) for measuring peroxisome Proliferator-Activated Receptor-Gamma (PPAR-gamma) — Through study completion up to end of study, when the last patients completed 1 year follow-up
    Measured either through biospy at baseline or from blood and urine samples taken at baseline, after 15 days, 2 months, 6 months and then every 6 months until the last patients completed 1 year follow-up. Its contribution for classifying ANCA vasculitis and other nephropathies will be evaluated.

Trial sites (1)

FacilityCityRegionStatus
Georges-Pompidou European Hospital, AP-HP Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs Starting soon
Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients Starting soon
Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL) Recruiting
French Cohort of Myocardial Infarction Evaluation Recruiting
Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine Recruiting

Other trials for the same condition

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Active, not recruiting
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial Recruiting
Atrasentan in Patients With IgA Nephropathy Active, not recruiting
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases Recruiting
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07010250 on ClinicalTrials.gov ↗ ← All trials in France